返回 Agenda
Module 2: Candidate Identification/Preclinical Testing
Session Chair(s)
Courtland R. LaVallee, MBA
Executive Director, Project Management
Dynavax Technologies, United States
- Discovery
- Drug Substance Scale up for Toxicology Testing
- Simple Formulation for Phase 1 Clinical Work
- Single Dose/MD Toxicity in Animals up to 14 or 30 Days
- Development of Biomarkers for Phase 1
- Summary